Literature DB >> 12131362

Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer.

A G Kennedy-Smith1, J L McKenzie, M C Owen, P J T Davidson, S Vuckovic, D N J Hart.   

Abstract

PURPOSE: Prostate specific antigen (PSA) is found in high concentration in prostate tissue and in semen, in which its physiological function appears to be liquefaction. In prostate cancer the peripheral PSA concentration is elevated, which may be used as a disease marker. Systemic and local immune defects have been demonstrated in prostate cancer and we postulated a role for PSA in this immunosuppression. We explored the effects of PSA on human T-lymphocyte proliferation in vitro.
MATERIALS AND METHODS: PSA was purified from normal seminal plasma using a modified chromatographic technique. The effect of PSA or control protein on lymphocyte responses to mitogens, tetanus toxoid and alloantigens was tested. The inhibitory effect observed was further explored by varying the time of PSA addition, denaturing PSA and including interleukin-2 and anti-PSA antibodies.
RESULTS: PSA suppressed in vitro phytohemagglutinin and alloantigen stimulated lymphocyte proliferation in a dose dependent manner. This effect was reversed by adding anti-PSA antibodies but not by interleukin-2.
CONCLUSIONS: These in vitro PSA effects suggest another T-lymphocyte mediated immunosuppressive mechanism. In vivo high levels of PSA may compromise natural immune responses to cancer and current attempts at immunotherapy for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131362

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

2.  Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.

Authors:  Jennifer D Wu; Lily M Higgins; Alexander Steinle; David Cosman; Kathy Haugk; Stephen R Plymate
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 3.  The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.

Authors:  Pierre-Olivier Gaudreau; John Stagg; Denis Soulières; Fred Saad
Journal:  Biomark Cancer       Date:  2016-05-05

Review 4.  Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Authors:  Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2014-05-06       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.